{"title":"CAR-T细胞介导免疫治疗的进展和挑战。","authors":"Dipayan Rudra, Himanshu Kumar","doi":"10.1080/08830185.2022.2111107","DOIUrl":null,"url":null,"abstract":"Immuno-oncology approaches involving engineered T cell-mediated immunotherapies have revolutionized anti-cancer clinical research in recent years. Among these, Chimeric Antigen Receptor (CAR)-T cell-based therapies have taken center stage in the field of immuno-therapeutics. The strategy involves ex-vivo engineering of T cells with CAR molecules, whose external domains are designed to recognize tumor-expressed antigens. Following the infusion of engineered CAR-T cells in patients, upon antigen recognition the internal signaling events initiated from the remaining intracellular CAR domains result in the activation of T cells, and finally elimination of tumor cells take place. The key advantages of this immuno-therapy are the selective recognition of tumor antigens and the elimination of tumor cells by autol-ogous engineered T cells. In this special issue of International Reviews of Immunology , we present five comprehensive review articles that summarize key advances in basic and translational aspects of CAR-T cell research (Figure 1).","PeriodicalId":14333,"journal":{"name":"International Reviews of Immunology","volume":null,"pages":null},"PeriodicalIF":4.3000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Advances and challenges in CAR-T cell-mediated immunotherapy.\",\"authors\":\"Dipayan Rudra, Himanshu Kumar\",\"doi\":\"10.1080/08830185.2022.2111107\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Immuno-oncology approaches involving engineered T cell-mediated immunotherapies have revolutionized anti-cancer clinical research in recent years. Among these, Chimeric Antigen Receptor (CAR)-T cell-based therapies have taken center stage in the field of immuno-therapeutics. The strategy involves ex-vivo engineering of T cells with CAR molecules, whose external domains are designed to recognize tumor-expressed antigens. Following the infusion of engineered CAR-T cells in patients, upon antigen recognition the internal signaling events initiated from the remaining intracellular CAR domains result in the activation of T cells, and finally elimination of tumor cells take place. The key advantages of this immuno-therapy are the selective recognition of tumor antigens and the elimination of tumor cells by autol-ogous engineered T cells. In this special issue of International Reviews of Immunology , we present five comprehensive review articles that summarize key advances in basic and translational aspects of CAR-T cell research (Figure 1).\",\"PeriodicalId\":14333,\"journal\":{\"name\":\"International Reviews of Immunology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":4.3000,\"publicationDate\":\"2022-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Reviews of Immunology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/08830185.2022.2111107\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Reviews of Immunology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/08830185.2022.2111107","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
Advances and challenges in CAR-T cell-mediated immunotherapy.
Immuno-oncology approaches involving engineered T cell-mediated immunotherapies have revolutionized anti-cancer clinical research in recent years. Among these, Chimeric Antigen Receptor (CAR)-T cell-based therapies have taken center stage in the field of immuno-therapeutics. The strategy involves ex-vivo engineering of T cells with CAR molecules, whose external domains are designed to recognize tumor-expressed antigens. Following the infusion of engineered CAR-T cells in patients, upon antigen recognition the internal signaling events initiated from the remaining intracellular CAR domains result in the activation of T cells, and finally elimination of tumor cells take place. The key advantages of this immuno-therapy are the selective recognition of tumor antigens and the elimination of tumor cells by autol-ogous engineered T cells. In this special issue of International Reviews of Immunology , we present five comprehensive review articles that summarize key advances in basic and translational aspects of CAR-T cell research (Figure 1).
期刊介绍:
This review journal provides the most current information on basic and translational research in immunology and related fields. In addition to invited reviews, the journal accepts for publication articles and editorials on relevant topics proposed by contributors. Each issue of International Reviews of Immunology contains both solicited and unsolicited review articles, editorials, and ''In-this-Issue'' highlights. The journal also hosts reviews that position the authors'' original work relative to advances in a given field, bridging the gap between annual reviews and the original research articles.
This review series is relevant to all immunologists, molecular biologists, microbiologists, translational scientists, industry researchers, and physicians who work in basic and clinical immunology, inflammatory and allergic diseases, vaccines, and additional topics relevant to medical research and drug development that connect immunology to disciplines such as oncology, cardiovascular disease, and metabolic disorders.
Covered in International Reviews of Immunology: Basic and developmental immunology (innate and adaptive immunity; inflammation; and tumor and microbial immunology); Clinical research (mechanisms of disease in man pertaining to infectious diseases, autoimmunity, allergy, oncology / immunology); and Translational research (relevant to biomarkers, diagnostics, vaccines, and drug development).